Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator

BACKGROUND: Navafenterol (AZD8871) is an inhaled long-acting dual-pharmacology muscarinic antagonist/β(2)-adrenoceptor agonist (MABA) in development for the treatment of obstructive airways diseases. The safety, tolerability, pharmacodynamics, and pharmacokinetics of navafenterol were investigated i...

Descripción completa

Detalles Bibliográficos
Autores principales: Jimenez, Eulalia, Astbury, Carol, Albayaty, Muna, Wählby-Hamrén, Ulrika, Seoane, Beatriz, Villarroel, Cristina, Pujol, Helena, Bermejo, Maria Jesus, Aggarwal, Ajay, Psallidas, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487994/
https://www.ncbi.nlm.nih.gov/pubmed/32907576
http://dx.doi.org/10.1186/s12931-020-01470-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7487994/
https://www.ncbi.nlm.nih.gov/pubmed/32907576
http://dx.doi.org/10.1186/s12931-020-01470-5

Ejemplares similares